Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register

Arthritis Care and Research

Volumn 64, Issue 8, 2012, Pages 1108-1115

  Soliman, Moetaza M ^a   Hyrich, Kimme L ^a   Lunt, Mark ^a   Watson, Kath D ^a   Symmons, Deborah P M ^a   Ashcroft, Darren M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUROPEAN LEAGUE AGAINST RHEUMATISM CRITERIA; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG SUBSTITUTION; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; SOCIETIES, MEDICAL; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864454091     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21663     Document Type: Article

References (22)

1. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL,. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 583-9.
2. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007; 66: 893-9.
3. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007; 46: 1191-9.
4. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ,. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20.
5. Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons DP,. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 2008; 47: 1000-5.
6. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
7. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
8. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
9. Assous N, Gossec L, Dougados M, Kahan A, Allanore Y,. Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-α drugs in daily practice: an open label observational study [letter]. Clin Exp Rheumatol 2007; 25: 504.
10. Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A,. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol 2007; 66: 476-83.
11. Valleala H, Korpela M, Mottonen T, Hienonen-Kempas T, Kauppi M, Hannonen P, et al. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. Scand J Rheumatol 2009; 38: 323-7.
12. Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, et al, on behalf of the physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007; 56: 1417-23.
13. Silman A, Symmons D, Scott DG, Griffiths I,. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003; 62 Suppl 2: ii28-9.
14. Bruce B, Fries JF,. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005; 23: S14-8.
15. Van Gestel AM, Haagsma CJ, van Riel PL,. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
17. Fransen J, Creemers MC, van Riel PL,. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 1252-5.
18. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA,. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 557-60.
19. Sato T, Matsuyama Y,. Marginal structural models as a tool for standardization. Epidemiology 2003; 14: 680-6.
20. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010; 69: 387-93.
21. Hyrich KL, Watson KD, Silman AJ, Symmons DP,. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
22. Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM,. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol 2012; 39: 240-6.